Loading...
Market
Will Lexeo Therapeutics' LX2006 achieve a mean LVMI reduction of at least 20% at 24 months by July 15, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Lexeo Therapeutics' official press releases or clinical trial publications
Story
Lexeo Therapeutics Reports Positive Interim Data for LX2006 with 18.3% LVMI Reduction at 18 Months
Jul 15, 2024, 10:03 AM
Lexeo Therapeutics has announced positive interim Phase 1/2 clinical data for its gene therapy, LX2006, aimed at treating Friedreich Ataxia Cardiomyopathy. The data revealed a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants who had elevated LVMI at baseline. Baird remains bullish on Lexeo, noting that levels approaching 20% would be a significant milestone. The Baird report suggests that the LX2006 update can provide further proof-of-concept. Despite some early data showing promise, there are concerns about the clarity of the results.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
